NASDAQ$EWTX

Edgewise Therapeutics Inc · Q4 2020 earnings

Q4 2020 earnings · · Investor relations

Headline financials

EPS (adj)

-$23.17

No prior period
Free Cash Flow

-$4.64M

No prior period
Net Income

-$6.34M

No prior period
Operating Income

-$6.34M

No prior period
Cash & Equivalents

$105M

No prior period
Total Assets

$131M

No prior period
Stock-Based Comp

$190K

No prior period

Revenue & EPS history

Edgewise Therapeutics · Revenue · Quarterly

$0

Q3 2025

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q4 2020

Historical avgQ4 2020

-0.2%

Avg return

Earnings day

+0.7%

Avg return

5 days after

-4.0%

Avg return

30 days after

40%

8 / 20 earnings

Positive

+16.0%

Q2 2022

Best reaction

-12.3%

Q1 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-1.7%-4.3%+2.4%
Q3 2025-1.7%+23.7%+35.8%
Q2 2025-4.1%-0.9%+15.2%
Q1 2025+2.4%+1.0%+5.8%
Q4 2024-2.4%+7.0%-40.7%
Q3 2024-0.7%-3.9%-11.0%
Q1 2024-12.3%-16.5%-15.5%
Q4 2023-1.3%-3.7%-7.1%
Q3 2023-10.7%+5.5%+13.0%
Q2 2023+3.4%+12.5%-3.4%
Q1 2023-6.5%-5.5%-2.8%
Q4 2022-3.0%-2.8%-30.3%
Q3 2022+1.8%+2.1%-5.7%
Q2 2022+16.0%+6.8%+17.1%
Q1 2022+1.6%-0.8%-18.9%
Q4 2021+13.0%-2.5%-19.3%
Q3 2021-1.8%-3.4%-3.1%
Q2 2021-5.6%-10.6%-7.9%
Q1 2021+5.2%+4.7%-1.6%
Q4 2020+5.2%+4.7%-1.6%
Q3 2020
Q2 2020
Q1 2020

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro